ClinicalTrials.gg
Not yet recruitingNCT07755124Updated Aug 10, 2026

Dietary Arginine Deprivation Combined With Chemoradiotherapy for Neoadjuvant Treatment of Rectal Cancer: A Randomized Controlled Trial

A Phase 1/2 interventional study of Arginine-Deprived Diet and Short-Course Radiotherapy (SCRT) in Rectal Neoplasms, sponsored by West China Hospital. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by West China Hospital · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Rectal Neoplasms by West China Hospital — 5 open to participants now, 6 under way, 3 of them phase 3. Rectal Neoplasms · West China Hospital.

Planned enrollment
6th of 12
140 · median 101
Started
2026
the only one that year
Phase 1/2
2 of 14
2 open now
Registered
14th of 14
by date

Among the 14 studies in Rectal Neoplasms by West China Hospital, this one is the 6th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2026, is one of 2 in phase 1/2, and was the 14th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

5 of the 14 studies in Rectal Neoplasms by West China Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Rectal Neoplasms by West China Hospital, or all of them as a file.
02

Study summary

This study evaluates whether an arginine-free diet combined with chemoradiotherapy can improve treatment outcomes in patients with locally advanced rectal cancer. Our previous study showed that an arginine-free diet is safe and may boost the body's immune response against tumors.

The study has two phases. The first phase (6 patients) tests the safety of the diet. The second phase (134 patients) randomly assigns participants to receive either the arginine-free diet plus standard chemoradiotherapy or standard chemoradiotherapy alone.

The arginine-free diet is provided as a liquid nutritional formula for 4 weeks. The main goal is to see if the diet increases the complete response rate (tumor disappearance). We will also evaluate survival outcomes, side effects, and quality of life.

03

Conditions studied

  • Rectal Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written prior to any study-related procedures.
  • Male or female, aged 18 to 80 years.
  • Locally advanced mid-low rectal cancer staged as cT3, cT4, or node-positive by rectal MRI.
  • performance status 0-1.
  • NRS-2002 score \< 3.
  • ≥ 18.5 kg/m² (may be adjusted based on actual conditions).
  • Able to take food orally or via feeding tube and tolerate enteral nutrition.
  • Adequate organ function as defined by the following laboratory criteria:

    1. ≥ 1.5 × 10⁹/L (no G-CSF within 14 days);
    2. count ≥ 100 × 10⁹/L;
    3. ≥ 9 g/dL (no transfusion or erythropoietin within 7 days);
    4. Serum albumin ≥ 3.0 g/dL;
    5. Total ≤ 1.5 × ;
    6. /ALT ≤ 2.5 × ULN;
    7. ≥ 50 mL/min or serum creatinine ≤ 1.5 × ULN;
    8. ≤ 1.5 × ULN, PT and APTT ≤ 1.5 × ULN;
    9. Urine protein \< 2+ (if ≥ 2+, 24-hour urine protein \< 2.0 g allowed);
    10. Cardiac enzyme profile within normal limits.
  • Women of must agree to use reliable from signing informed consent to at least 6 months after the last dose, with a negative serum HCG test within 3 days before treatment and non-lactating status.
  • All participants at risk of pregnancy must use contraceptive methods with a failure rate of \< 1% per year throughout treatment until 120 days after the last study drug dose (or 180 days after the last chemotherapy).

Exclusion criteria

Exclusion Criteria:

  • Stage I or IV rectal cancer.
  • Cognitive impairment or psychiatric disorders that interfere with understanding the study content.
  • Central nervous system or meningeal .
  • Clinically symptomatic moderate or severe ascites (requiring therapeutic paracentesis within 2 weeks before starting study treatment; patients with minimal asymptomatic ascites on imaging may be enrolled).
  • Uncontrolled or moderate to severe pleural effusion and pericardial effusion.
  • Severe diarrhea, intractable vomiting, severe malabsorption syndrome, paralytic or mechanical intestinal obstruction; tracheoesophageal fistula, gastrointestinal perforation or fistula, or intra-abdominal abscess; gastrointestinal bleeding with grade ≥ 3 within 6 months or CTCAE grade ≥ 2 within 3 months before study treatment.
  • Other factors that may affect study results or cause forced termination (as judged by the investigator), such as alcoholism, drug abuse, other serious diseases requiring combined treatment (including psychiatric disorders), severe laboratory abnormalities, family or social factors, and other conditions that may affect patient safety or study data collection.
  • Known allergy to active ingredients or of the study drug or nutritional powder.
  • Poorly controlled diabetes mellitus.
  • Severe cardiovascular and cerebrovascular diseases, including cerebrovascular accident (CVA), (TIA), myocardial infarction, and major vascular diseases within 6 months before enrollment; poorly controlled symptomatic cardiac diseases, such as unstable angina, class ≥ II heart failure, \< 50% on echocardiography, or severe arrhythmia uncontrolled by medication.
  • Pregnancy or lactation.
  • Other conditions deemed unsuitable for enrollment by the investigator.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Arginine-Deprived Diet + Chemoimmunotherapy + SCRT

    Dietary Supplement: Arginine-Deprived Diet · Radiation: Short-Course Radiotherapy (SCRT) · Drug: CAPOX + PD-1 Inhibitor

  • Active comparator
    Standard Chemoimmunotherapy with SCRT

    Participants in the control arm receive standard chemoradiotherapy with normal diet. The treatment regimen includes CAPOX chemotherapy (oxaliplatin 130 mg/m² IV on day 1 + capecitabine 1000 mg/m² oral twice daily on days 1-14) combined with PD-1 inhibitor (200 mg IV on day 1) every 3 weeks for 6 cycles, plus short-course radiotherapy (25 Gy in 5 fractions) in the first week of cycle 2. Diet is unrestricted. No arginine-deprived diet is administered.

    Radiation: Short-Course Radiotherapy (SCRT) · Drug: CAPOX + PD-1 Inhibitor

Interventions

  • Dietary supplementArginine-Deprived Diet

    A nutritionally complete liquid formula providing 1978 kJ energy, 16.6 g protein, 22.2 g fat, 49.4 g carbohydrate, and 4.32 g dietary fiber per 100 g, with all essential amino acids except arginine. Participants receive the formula as a total diet replacement for 4 weeks during chemoradiotherapy. Daily intake is calculated based on standard body weight at 30 kcal/kg/day energy and 1.5 g/kg/day protein, typically 3.5-8.5 bottles per day (70 g/bottle, reconstituted in 300 mL warm water).

  • RadiationShort-Course Radiotherapy (SCRT)

    Short-course radiotherapy delivered at 25 Gy in 5 fractions over 5 consecutive days during the first week of Cycle 2 (C2D1-C2D5, day 21-28 of the treatment schedule).

  • DrugCAPOX + PD-1 Inhibitor

    Drug page: Immune checkpoint inhibitorsStudies of Immune checkpoint inhibitorsImmune checkpoint inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    CAPOX regimen (oxaliplatin 130 mg/m² IV on day 1 + capecitabine 1000 mg/m² oral twice daily on days 1-14) combined with PD-1 inhibitor (200 mg IV on day 1) every 3 weeks for 6 cycles.

06

What researchers measure

Primary outcomes

  1. Complete Response (CR) Rate (pCR + cCR)

    Complete response rate is defined as the proportion of participants achieving either pathological complete response (pCR) or clinical complete response (cCR). pCR is defined as no residual tumor cells in the resected tumor tissue and regional lymph nodes. cCR is defined as no evidence of residual tumor in the primary lesion and regional lymph nodes (ycT0N0) after neoadjuvant treatment, assessed by rectal examination, endoscopy, pelvic MRI (T2WI/DWI), and serum CEA level.

    Time frame: From enrollment to postoperative pathological assessment, approximately 6 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Aug 2028, 24 months later.

Of 37 phase 1/2 interventional studies under Rectal Neoplasms, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 106. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2026
First posted
Aug 10, 2026
StartEst.
Aug 14, 2026
Primary completionEst.
Aug 2028
CompletionEst.
Jun 30, 2029
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07755124
Responsible party
Xuelei Ma MD (Biotherapy Department, Deputy Director, West China Hospital) — Principal investigator
First posted
Aug 10, 2026
Start date
Aug 14, 2026 (estimated)
Primary completion
Aug 2028 (estimated)
Completion
Jun 30, 2029 (estimated)
Last update
Aug 10, 2026

Study contacts

Xuelei Ma
Contact
drmaxuelei@gmail.com
+86 13408410416

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion